DeepMed Research

SPECTRUM PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1987-01-01

Employees: 101

Market Cap: -

Website: http://www.sppirx.com

Clinical Trials

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

Phase 3

Suspended

Conditions: NSCLC

Interventions: Drug: Poziotinib
Drug: Docetaxel

First Posted Date: 2022-05-18

Last Posted Date: 2025-05-23

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 268

Registration Number: NCT05378763

Locations: 🇺🇸
Bond Clinic, P.A., Winter Haven, Florida, United States

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Poziotinib
Drug: Itraconazole
Drug: Phenytoin
Drug: Paroxetine

First Posted Date: 2021-07-29

Last Posted Date: 2021-09-05

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 74

Registration Number: NCT04981704

Locations: 🇺🇸
Celerion, Phoenix clinical facility, Tempe, Arizona, United States

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Phase 2

Recruiting

Conditions: Solid Tumors
Lymphoma

Interventions: Drug: Eflapegrastim
Drug: Chemotherapy

First Posted Date: 2020-09-30

Last Posted Date: 2025-05-23

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 40

Registration Number: NCT04570423

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
Carolinas Medical Center/ Levine Children's Hospital, Charlotte, North Carolina, United States

and more 1 locations

Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-Poziotinib

First Posted Date: 2020-06-18

Last Posted Date: 2021-01-15

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 8

Registration Number: NCT04436562

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States

Study of Poziotinib in Japanese Patients With NSCLC

Phase 1

Terminated

Conditions: NSCLC

Interventions: Drug: Poziotinib Twice Daily Dosing
Drug: Poziotinib Once Daily Dosing
Drug: Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1

First Posted Date: 2020-05-26

Last Posted Date: 2024-06-25

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 42

Registration Number: NCT04402008

Locations: 🇯🇵
Shizuoka Cancer Center, Sunto District, Shizuoka, Japan
🇯🇵
National Cancer Center East, Kashiwa, Chiba, Japan
🇯🇵
Osaka City General Hospital, Miyakojima-ku, Osaka, Japan

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Phase 1

Active, not recruiting

Conditions: Neutropenia
Breast Cancer

Interventions: Biological: Eflapegrastim
Drug: Docetaxel
Drug: Cyclophosphamide

First Posted Date: 2019-12-05

Last Posted Date: 2024-07-11

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 50

Registration Number: NCT04187898

Locations: 🇺🇸
BRCR Medical Center, Inc., Plantation, Florida, United States
🇺🇸
City of Hope, Long Beach, California, United States
🇺🇸
Mercy Health Youngstown, Youngstown, Ohio, United States

and more 5 locations

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Phase 2

Terminated

Conditions: Breast Cancer
Colorectal Cancer
Solid Tumor
Glioblastome Multiforme

Interventions: Drug: Poziotinib Hydrochloride
Drug: Loperamide

First Posted Date: 2019-11-21

Last Posted Date: 2024-03-13

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 1

Registration Number: NCT04172597

Locations: 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States

A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: 14C-labeled poziotinib

First Posted Date: 2019-01-15

Last Posted Date: 2021-06-15

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 2

Registration Number: NCT03804515

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Phase 2

Terminated

Conditions: NSCLC
Breast Cancer

Interventions: Drug: Poziotinib

First Posted Date: 2018-11-16

Last Posted Date: 2024-03-05

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 7

Registration Number: NCT03744715

Locations: 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
🇺🇸
Hattiesburg Clinic Hematology Oncology, Hattiesburg, Mississippi, United States

and more 2 locations

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: Poziotinib
Drug: T-DM1

First Posted Date: 2018-02-12

Last Posted Date: 2021-01-15

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 6

Registration Number: NCT03429101

Locations: 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸
Los Angeles Hematology Oncology Medical Group, Glendale, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy